Bioventus (BVS) CFO vests 18,625 RSUs with 8,091 shares withheld for taxes
Mark Leonard Singleton, CFO of Bioventus Inc. (BVS), exercised 18,625 Restricted Stock Units (RSUs) on March 20, 2026. For tax purposes related to this vesting, 8,091 shares were withheld at a price of $8.64 per share. Following these transactions, Singleton directly holds 169,981 shares of Bioventus Class A common stock.
Bioventus (BVS) CEO adds major RSU and option grants, exercises awards
Bioventus Inc. CEO Robert E. Claypoole reported significant equity compensation changes in a recent SEC filing. On March 13, 2026, he exercised 33,500 restricted stock units, leading to 14,553 shares being withheld for tax obligations, leaving him with 135,944 Class A shares. Additionally, he received new grants of 278,000 restricted stock units and 309,000 stock options, which will vest over four years subject to his continued service.
Bioventus (BVS) CFO receives major stock awards and exercises RSUs
Bioventus Inc. CFO Mark Leonard Singleton reported significant equity compensation activities, including receiving 104,000 restricted stock units and an option for 116,000 shares on March 13, 2026. He also exercised 13,500 RSUs, with some shares withheld for tax purposes, bringing his direct holdings to 159,447 shares of Class A common stock. These awards and options are subject to a four-year vesting schedule tied to his continued service.
Bioventus (BVS) SVP granted RSUs, options and exercises prior awards
Bioventus Inc.'s Senior Vice President and Chief Compliance Officer, Katrina J. Church, received new grants of 24,000 restricted stock units and 27,000 stock options, both vesting in four annual installments starting March 15, 2026. She also exercised 6,955 previously awarded restricted stock units, with 3,022 shares withheld for tax obligations. Following these transactions, Church directly holds 61,732 shares of Class A common stock.
Bioventus (BVS) SVP & General Counsel receives RSU, option grants and exercises awards
Bioventus Inc.'s SVP and General Counsel, Anthony D'Adamio, reported new equity compensation. He received grants of 83,000 restricted stock units (RSUs) and 92,000 stock options, and also exercised 8,886 and 8,750 RSUs into Class A shares, with some shares withheld for tax obligations. Following these transactions, D'Adamio directly owned 148,042 shares of Bioventus Class A common stock.
Bioventus (BVS) director logs open-market sale of 12,000 shares
Bioventus Inc. director Michelle McMurry-Heath reported an open-market sale of 12,000 shares of Class A common stock at a weighted average price of $8.7866. The shares were sold in multiple trades ranging from $8.73 to $8.81. Following this transaction, she now directly holds 44,997 shares.
Bioventus Q4 Earnings Assessment
Bioventus (NASDAQ: BVS) announced its Q4 earnings, beating estimated EPS by 9.09% with $0.24 versus an estimate of $0.22, and revenue was up $4.26 million year-over-year. The company has a history of beating EPS estimates and provided FY 2026 guidance expecting earnings between $0.73 and $0.77 per share.
Bioventus Earnings Report: Q4 Overview
Bioventus (NASDAQ: BVS) released its Q4 earnings report, announcing an EPS of $0.24, beating the estimate of $0.22 by 9.09%. Revenue increased by $4.26 million year-over-year. The company also provided guidance for FY 2026, forecasting earnings between $0.73 and $0.77 per share.
BVS SEC Filings - Bioventus Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Bioventus Inc. (BVS) SEC filings, including 10-K, 10-Q, 8-K, and Form 4 documents, with AI-powered summaries. It details key financial data, financing arrangements like credit agreements, and governance changes from recent filings. The article also provides recent filings such as the Q3 2025 earnings report and FDA clearance for two new medical devices.
Preview: Bioventus's Earnings
Bioventus (NASDAQ: BVS) is scheduled to release its quarterly earnings report on Thursday, March 5, 2026, with analysts estimating an EPS of $0.22. The article provides an overview of the company's past earnings performance, stock analysis, and financial metrics, including revenue growth, net margin, return on equity, return on assets, and debt management. Bioventus is a medical technology company specializing in treatments that enhance the body's natural healing process.
Bioventus 10-K: $568.1M Revenue, $0.33 Diluted EPS
Bioventus (BVS) reported fiscal year net sales of $568.1 million, remaining flat year-over-year, and achieved net income of $27.3 million, or $0.33 diluted earnings per share. This financial performance marks a significant recovery from a loss in the previous year, driven by improved operating income, cost controls, and strategic portfolio actions. The company also saw volume growth in Pain Treatments and Surgical Solutions, along with the divestiture of its non-core Advanced Rehabilitation business.
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
Bioventus reported strong financial results for Q4 and the full year 2025, with Q4 revenue increasing 2.8% to $157.9 million and organic revenue up 10.0%. Full-year 2025 revenue was $568.1 million, with 7.5% organic growth. The company strengthened its balance sheet, reduced debt, and provided optimistic 2026 guidance including projected net sales of $600 million to $610 million.
Bioventus Inc. to Report Fourth Quarter Fiscal Year 2025 Financial Results on March 5, 2026
Bioventus Inc. will release its Q4 fiscal year 2025 financial results on March 5, 2026, before the market opens, followed by a conference call at 8:30 a.m. Eastern Time. The company will discuss its financials and provide a business update, with a live webcast available on its investor relations website and archived for replay until March 4, 2027. The article also provides recent insider trading activity, revenue data, and institutional investor changes for BVS.
Bioventus (BVS) SVP & General Counsel exercises RSUs, withholds 6,327 shares for taxes
Anthony D'Adamio, SVP & General Counsel of Bioventus Inc. (BVS), acquired 12,980 shares of Class A common stock through the exercise of restricted stock units (RSUs) on February 15, 2026. On the same day, he disposed of 6,327 shares at $8.27 each for tax withholding purposes. Following these transactions, D'Adamio directly holds 138,069 shares of Bioventus Class A common stock.
Bioventus (BVS) SVP gets 4,375 shares, withholds 2,133 for tax
Bioventus Inc.'s SVP and Chief Compliance Officer, Katrina J. Church, exercised 4,375 restricted stock units, converting them into Class A common shares. Concurrently, 2,133 Class A shares were disposed of at $8.27 per share to cover tax obligations. Following these transactions, Church directly holds 57,799 Class A common shares and 8,750 restricted stock units.
Nantahala discloses 9.03% Bioventus (BVS) stake in Schedule 13G/A
Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a 9.03% beneficial ownership stake in Bioventus Inc. (BVS) Class A common stock through an amended Schedule 13G/A filing. As of December 31, 2025, they beneficially own 6,047,403 shares, holding shared voting and dispositive power. The securities were acquired and are held in the ordinary course of business, not for influencing control of Bioventus.
Bioventus Reports Second Quarter Financial Results
Bioventus has announced strong financial results for the second quarter of 2024, showing significant growth in revenue and profitability, particularly in its Pain Treatments and Surgical Solutions segments. Despite reporting a net loss due to an impairment charge and litigation costs, the company increased its adjusted EBITDA and raised its full-year financial guidance. Key strategic initiatives include the potential divestiture of its Advanced Rehabilitation Business and the FDA clearance of OSTEOAMP Cannula, aiming to enhance shareholder value and focus on core strengths.
Anderson Financial Strategies LLC Invests $901,000 in Bioventus Inc. $BVS
Anderson Financial Strategies LLC has acquired a new stake of 134,720 shares in Bioventus Inc. (NYSE:BVS) during the third quarter, valued at approximately $901,000. This investment represents about 0.16% ownership of Bioventus and constitutes roughly 0.5% of Anderson Financial Strategies LLC's portfolio. Meanwhile, two directors, Guy P. Nohra and Michelle Mcmurry-Heath, recently reduced their holdings in Bioventus through stock sales.
Recent uptick might appease Bioventus Inc. (NASDAQ:BVS) institutional owners after losing 13% over the past year
Institutional investors own 36% of Bioventus Inc. (NASDAQ:BVS), making the stock vulnerable to their trading decisions. The top 5 shareholders collectively own 52% of the company, with Essex Woodlands Management, Juniper Investment Company, and Smith & Nephew plc being the largest. Despite a 13% loss over the past year, a recent US$55m market cap gain might be welcomed by these institutional owners.
HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Bioventus Inc. (NASDAQ: BVS) breached their fiduciary duties to shareholders. The firm encourages current Bioventus stockholders, especially long-term shareholders, to contact them to discuss potential legal rights and options, including seeking corporate governance reforms or financial incentives. Halper Sadeh LLC emphasizes that shareholder involvement can improve company oversight and enhance shareholder value.
Bioventus appoints Ajay Dhankhar to board as Class II director
Bioventus Inc. has appointed Ajay Dhankhar, PhD, as a Class II director to its board, effective Thursday. Dr. Dhankhar, currently Chief Corporate Development & Strategy Officer at Smith & Nephew plc, will serve until the 2026 annual meeting of stockholders. This appointment aligns with a Stockholders Agreement allowing Smith & Nephew to designate directors, with Dr. Dhankhar being their second designee.
Bioventus Appoints Ajay Dhankhar as New Director
Bioventus Inc. (BVS) has appointed Ajay Dhankhar, PhD, as a Class II director, effective November 14, 2025. This appointment aligns with the Stockholders Agreement, which allows Smith & Nephew affiliates to designate directors. Dr. Dhankhar will not receive compensation for his role.
Bioventus Inc. Appoints Ajay Dhankhar to Board of Directors
Bioventus Inc. announced the appointment of Ajay Dhankhar, PhD, to its Board of Directors as a Class II director, effective November 14, 2025. Dr. Dhankhar will serve until the 2026 annual meeting of stockholders and brings experience as Chief Corporate Development & Strategy Officer at Smith & Nephew plc. This appointment was officially filed with the SEC on November 17, 2025.
Bioventus (BVS): $17.3M One-Time Loss Raises Questions About Quality of New Profitability
Bioventus (BVS) recently returned to profitability despite a one-time loss of $17.3 million, raising questions about the quality of these new earnings. The company faces significant debt, which poses a threat to future R&D and market responsiveness. Despite trading at a steep discount to fair value, its high P/E ratio and debt burden warrant caution among investors.
Bioventus Inc. SEC 10-Q Report
Bioventus Inc. has released its Form 10-Q report for the third quarter of 2025, highlighting stable financial performance with improvements in operating income and a positive net income turnaround. The company's U.S. segment remains the primary revenue driver, particularly in Pain Treatments and Surgical Solutions, which are also targeted for future growth alongside international expansion.
BVS Stock Quote Price and Forecast
This article provides a detailed financial overview and forecast for Bioventus, Inc. (BVS), including its current stock price, recent performance, key financial metrics, and a compilation of recent news and analyst ratings. It highlights the company's operational segments and its position within the medical technology sector.
Head-To-Head Survey: Bioventus (NASDAQ:BVS) & Shoulder Innovations (NYSE:SI)
This article provides a head-to-head comparison of Bioventus (NASDAQ:BVS) and Shoulder Innovations (NYSE:SI), examining their institutional ownership, insider ownership, earnings, valuation, analyst recommendations, and profitability. The analysis concludes that Bioventus outperforms Shoulder Innovations on 7 out of 12 factors discussed. Detailed company profiles are also included.
Bioventus Secures Dual FDA Clearance for Revolutionary Non-Opioid Pain Management Technology
Bioventus (Nasdaq: BVS) has received FDA 510(k) clearances for two new peripheral nerve stimulation (PNS) products, TalisMann™ and StimTrial™, for chronic pain management. These clearances position Bioventus to tap into a PNS market projected to exceed $500 million by 2029 with over 20% annual growth. The company plans a limited commercial release in Q3 2025, followed by a broader rollout in early 2026, offering non-opioid, minimally invasive therapies.
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
Bioventus reported strong financial results for the fourth quarter and full year 2024, with worldwide revenue increasing by 13.5% and 11.9% respectively, driven by growth in Pain Treatments and Surgical Solutions. The company also announced an increase in Adjusted EBITDA and provided optimistic financial guidance for 2025, anticipating continued revenue growth and operating margin expansion. These results follow strategic moves including the divestiture of its Advanced Rehabilitation Business and debt reduction.
Bioventus CFO Mark Leonard sells $113,018 in stock
Bioventus CFO Mark Leonard recently sold 10,733 shares of the company's Class A common stock, valued at $113,018. The company has seen its stock surge over 90% in the last six months and is expected to become profitable this year. Bioventus also reported strong third-quarter 2024 results, including a 15% year-over-year revenue increase and raised full-year guidance, highlighting its strong financial health and strategic growth initiatives.
Bioventus SVP Katrina Church sells $26,693 in stock By Investing.com
Katrina J. Church, SVP and Chief Compliance Officer at Bioventus Inc. (NASDAQ: BVS), sold 2,535 shares of company stock for $26,693 to cover taxes on vested restricted stock units. This transaction occurred after Bioventus saw a 102% gain over the past year and raised its full-year revenue guidance to between $562 million and $567 million due to strong Q3 growth. The company reported a 15% year-over-year increase in Q3 revenue to $139 million, driven by surgical solutions and the HA business.
Shareholder lawsuit ends with $15 million settlement
A federal judge has approved a $15.25 million settlement in a shareholder lawsuit against Durham-based Bioventus. The lawsuit alleged that the company misled shareholders regarding its financial performance. This settlement concludes the legal claims against the company.
Bioventus Inc. SEC 10-Q Report
Bioventus Inc. has released its Q3 2024 Form 10-Q report, detailing significant financial growth with net sales reaching $138.964 million for the quarter and $419.638 million year-to-date, marking an improvement in net loss compared to the prior year. The report highlights strategic initiatives like the divestiture of non-core assets to improve liquidity and reduce debt, new product launches, and regulatory approvals. However, the company also acknowledges challenges such as impairment charges related to divestitures, regulatory compliance costs, and potential dilution of ownership interests.
Bioventus reaches $15.25 million settlement in securities lawsuit
Bioventus Inc. has agreed to a $15.25 million settlement in a securities class action lawsuit, resolving claims related to rebate practices, financial prospects, and internal controls. While the settlement requires court approval and does not admit liability, it aims to conclude litigation dating back to January 2023. This development occurs as Bioventus reports strong financial performance in Q1 2024 and significant corporate governance changes.
Durham company agrees to $15 million settlement in shareholder lawsuit
A Durham company, Bioventus, has agreed to a $15 million settlement in a shareholder lawsuit. The lawsuit alleged that the company misstated its financial results, leading to an artificially inflated stock price. This settlement addresses claims related to these financial misrepresentations.
Bioventus Deserves A Look After A Beat And Raise Report
Bioventus Inc. reported strong financial results for the first quarter of 2024, exceeding analyst expectations for revenue and significantly reducing its net loss. Based on this performance, the company has raised its full-year 2024 revenue and non-GAAP EPS forecasts, indicating confidence in continued growth. The stock saw a significant increase following the report.
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
Bioventus Inc. announced the issuance of inducement equity awards to Robert Claypoole in connection with his appointment as President, Chief Executive Officer, and Principle Executive Officer. The awards consist of 375,000 restricted share units and options to purchase 850,000 shares of the Company’s Class A common stock. These awards will vest in four equal installments over four years, subject to his continued employment.
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Bioventus Inc. (NASDAQ: BVS) on behalf of long-term stockholders following a class action complaint filed in January 2023. The investigation concerns potential breaches of fiduciary duties by Bioventus's board of directors, stemming from alleged misleading statements in IPO documents regarding liquidity issues, unsustainable rebate practices, and inadequate internal controls. These issues led to significant stock price declines and investor losses.
Bioventus Announces CEO Leadership Change
Bioventus Inc. announced that Ken M. Reali has stepped down as CEO and board member. The board has initiated a search for a permanent CEO and appointed Anthony Bihl as interim CEO. Bihl previously served as CEO of Bioventus LLC and aims to stabilize the company and improve execution.
Bioventus Announces CEO Leadership Change
Bioventus Inc. announced that Ken M. Reali has stepped down as CEO and board member. Anthony Bihl, former CEO of Bioventus LLC, has been appointed interim CEO while the board searches for a permanent successor. The company aims to address performance, unlock long-term value, and enhance shareholder value under Bihl's interim leadership.
BVS DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Bioventus Inc. Investors with Losses to Secure Counsel Before Important March 13 Deadline in Securities Class Action - BVS
Rosen Law Firm is reminding investors who purchased Bioventus Inc. (NASDAQ: BVS) securities during the Class Period (February 11, 2021, and November 21, 2022) that the lead plaintiff deadline for a securities class action lawsuit is March 13, 2023. The lawsuit alleges that Bioventus suffered from significant liquidity issues, unsustainable rebate practices, and deficient disclosure controls, which led to an overstatement of the company's business and financial prospects. Investors are encouraged to secure counsel before the deadline to potentially recover losses.
BIOVENTUS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Bioventus Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announced a class action lawsuit against Bioventus Inc. (NASDAQ: BVS) for investors who purchased securities around its February 11, 2021 IPO. The lawsuit alleges that Bioventus's offering documents contained misleading statements and failed to disclose significant liquidity issues, unsustainable rebate practices, and deficient internal controls, which led to a substantial drop in stock price. Investors have until March 13, 2023, to apply to be a lead plaintiff.
Bioventus Deadline Alert
Faruqi & Faruqi, LLP is investigating potential securities claims against Bioventus Inc. (NASDAQ: BVS) and reminds investors that the deadline to seek the role of lead plaintiff in a federal securities class action is March 13, 2023. The investigation is focused on losses exceeding $100,000 for investors who purchased Bioventus Class A common stock during its IPO on or about February 11, 2021, and/or Bioventus securities between February 11, 2021, and November 21, 2022, due to alleged false and misleading statements and omissions in the company's offering documents and public statements.
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Bioventus Inc. Investors to Secure Counsel Before Important March 13 Deadline in Securities Class Action - BVS
Rosen Law Firm is encouraging investors of Bioventus Inc. (NASDAQ: BVS) to join a securities class action lawsuit before the March 13, 2023 lead plaintiff deadline. The lawsuit alleges that Bioventus made false and misleading statements in its offering documents and during the Class Period, particularly regarding liquidity issues, unsustainable rebate practices, and deficient financial controls, leading to investor damages. Investors who purchased Bioventus securities during the specified period may be entitled to compensation.
ROSEN, A LEADING LAW FIRM, Encourages Bioventus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BVS
Rosen Law Firm is encouraging investors of Bioventus Inc. to secure legal counsel before the March 13, 2023 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Bioventus made false and misleading statements in its offering documents and during the Class Period (February 11, 2021, to November 21, 2022) regarding its liquidity, rebate practices, and financial reporting. Investors who purchased Bioventus securities during this period may be entitled to compensation.
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz is reminding investors of upcoming deadlines to file lead plaintiff motions in class action lawsuits against ESS Tech, Inc. (GWH), Bioventus Inc. (BVS), Y-mAbs Therapeutics, Inc. (YMAB), and Fate Therapeutics, Inc. (FATE). The lawsuits allege that these companies made materially false and misleading statements to investors. Shareholders who suffered losses are encouraged to contact the firm to discuss their legal rights.
DEADLINE ALERT for LUV, GWH, BVS, and YMAB: The Law Offices
The Law Offices of Frank R. Cruz issued a deadline alert for class action lawsuits against Southwest Airlines Co. (LUV), ESS Tech, Inc. (GWH), Bioventus Inc. (BVS), and Y-mAbs Therapeutics, Inc. (YMAB). Investors in these companies have until March 13 or March 20, 2023, to file a lead plaintiff motion. The lawsuits allege that these companies made materially false and/or misleading statements and failed to disclose critical information regarding their business operations and prospects.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline - BVS
Pomerantz LLP has filed a class action lawsuit against Bioventus Inc. and certain officers and directors, alleging that the company made false and misleading statements in its IPO documents and throughout the class period. Shareholders who purchased Bioventus Class A common stock during the specified period have until March 13, 2023, to apply to be lead plaintiff. The lawsuit claims Bioventus suffered from liquidity issues, unsustainable rebate practices, and deficient disclosure controls, leading to a significant stock price decline.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Bioventus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BVS
Rosen Law Firm is encouraging Bioventus Inc. investors to join a securities class action lawsuit before the March 13, 2023 lead plaintiff deadline. The lawsuit alleges that Bioventus made false and misleading statements in its offering documents and during the Class Period, particularly regarding liquidity issues, unsustainable rebate practices, and deficient internal controls, which led to investor damages. Investors who purchased Bioventus securities between February 11, 2021, and November 21, 2022, may be entitled to compensation.
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION
Bernstein Liebhard LLP has reminded investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit against Bioventus Inc. (NASDAQ: BVS). The lawsuit alleges that Bioventus made false and misleading statements regarding its liquidity, rebate practices, and financial prospects during its IPO and subsequent Class Period, leading to significant stock price drops. Investors who purchased Bioventus securities between February 11, 2021, and November 21, 2022, are encouraged to contact the firm to discuss their rights.
